✂️ Sanofi culls several programs: The move comes as part of its “regular portfolio reviews,” a spokesperson said in an email. One candidate affected was

The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted

Post Content

Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million

AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that’s become a go-to place for drug R&D